Daiichi Sankyo Announces Phase III Trial Demonstrating Superior Efficacy of Prasugrel Over Clopidogrel in Thrombotic Stroke Patients
Jul 22, 2020 18:32
CST Updated
18:32
Daiichi-Sankyo
Pharmaceutical R&D Developer
July 21, 2020 News /BioValleyBIOON/ -- Daiichi Sankyo recently announced that the Japanese Phase 3 PRASTRO-III study, which evaluated the antiplatelet drug prasugrel in patients with thrombotic stroke, met its primary endpoint.
This was a double-blind, controlled study conducted in 234 patients with thrombotic stroke who had one or more risk factors for recurrent ischemic stroke, comparing the efficacy and safety of prasugrel versus clopidogrel.
The results showed that the study met its primary endpoint: cerebrovascular events (such as ischemic stroke) in the prasugrel treatment group,Myocardial InfarctionThe incidence of (and other vascular deaths) was lower than that in the clopidogrel treatment group. No other safety issues were identified in this study.
The complete results of this study will be presented at future academic conferences.Meetingand published in publications. Daiichi Sankyo will continue to strive to provide new treatment options for patients with thrombotic stroke.
Although ischemic stroke is caused by multiple factors, thrombotic stroke is characterized by the occlusion of cerebral blood vessels primarily due to platelet thrombi resulting from atherosclerosis.
Prasugrel is a medication used to inhibit platelet aggregation. As a new-generation thienopyridine and a competitive P2Y12 receptor inhibitor, it effectively controls systemic inflammation, reduces the risk of arterial thrombosis, and significantly decreases the incidence of ischemic events.
Furthermore, compared with clopidogrel, prasugrel requires only a single metabolic step to be converted into its active metabolite, which means it has a more potent antiplatelet effect and a shorter onset of action, thereby providing superior efficacy against myocardial ischemia. (Bioon.com)